DRIVIN G ROWTH - Dr. Reddy's

WITH THE ANTICIPATED GROWTH IN THE GLOBAL GENERICS
BUSINESS AFTER 2005 — WHEN A LARGE NUMBER OF
FORMULATIONS GO OFF-PATENT — THE COMPANY’S APIS
BUSINESS SHOULD SEE SIGNIFICANT GROWTH.
Table 5
|
India Revenue by
therapeutic segments
RS. MILLION
REVENUE SHARE
Cardio-vascular 939 23%
Pain management 785 19%
Gastro-intestinal 751 19%
Anti-infective 666 16%
Specialty 538 13%
Naturals 363 10%
Total 4,042 100.0%
sixth in the Indian formulations market,
with a market share of 2.6 per cent.
CMARC’s prescription audit puts the
Company in fifth place. Two of the
Company’s brands occupy positions among
the top-20 pharmaceutical brands in India;
10 are brand leaders; 11 occupy second
position; while two are in the third position.
The top-10 brands accounted for 53 per
cent of the segment’s domestic sales
revenue. Table 4 gives the data. Table 5
gives revenues by therapeutic segments.
GENERICS
MUCH HAS BEEN ALREADY written
on Dr. Reddy’s generics business in the
earlier pages. The overall revenue from this
segment was Rs. 4,066 million in 2001-02,
compared to Rs. 304 million in the
previous year — driven largely by the sale
of fluoxetine
capsules 40 mg in
the US, which
contributed 81 per cent to the total generics
turnover. Excluding fluoxetine, revenue
was at to Rs. 780 million.
Besides fluoxetine, Dr. Reddy’s
successfully launched several other generic
products in 2001-02. Some of these are: (i)
famotidine tablets 10 mg(OTC), 20 mg and
40 mg in the US, (ii) omeprazole capsules
10 mg and 20 mg, ciprofloxacin tablets
100 mg, 250 mg, 500 mg and 750 mg,
and Ranitidine tablets 75 mg in South
Africa, and (iii) norfloxacin tablets
400 mg in Australia.
DR. REDDY’S LABORATORIES LTD. | MANAGEMENT DISCUSSION AND ANALYSIS | ANNUAL REPORT 2001-2002
53